AI medical imaging analysis company AIDOT (CEO: Jaehun Jung) announced its participation in KIMES 2026, where it will showcase its flagship solution, Cerviray AI, and demonstrate its technological capabilities in medical AI.

During the exhibition, AIDOT will be located at Booth C428 within the Korea Health Industry Development Institute pavilion on the 3rd floor of COEX. Visitors will have the opportunity to experience Cerviray AI firsthand, along with detailed introductions to its key features and clinical applications.

Cerviray AI is an AI-powered cervical cancer diagnostic support solution that has received Class III approval from the MFDS (Korea’s Ministry of Food and Drug Safety). It uniquely scans the cervix, automatically detects suspected lesion areas, and provides a four-stage classification result to assist clinical decision-making.

A key differentiator of Cerviray AI is its on-device AI capability, enabling analysis and results without the need for an internet connection. This design allows for efficient deployment in diverse clinical environments, including settings with limited medical infrastructure or varying operational conditions.

Through its participation in KIMES 2026, AIDOT aims to directly demonstrate the clinical applicability and technological competitiveness of Cerviray AI, while also highlighting its future business scalability.

Building on Cerviray AI, the company continues to expand its presence in both domestic and global markets, accelerating efforts to strengthen its global competitiveness.

An AIDOT representative stated, “Through KIMES 2026, we aim to introduce Cerviray AI’s technology and real-world usability to a broader range of healthcare professionals. We will continue to advance AI solutions that provide meaningful clinical value and expand our presence in global markets.”

Korea Economic TV / 2026-03-19 / Yang Jaejun, Deputy Managing Editor